Physician profile
Graeme Mindel
NPI 1932196854
$2,122.73
in general payments reported to CMS, 2019-2025
19 companies · $666 in 2025
The $666 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $43.19 · 2021: $108 · 2022: $149 · 2023: $444 · 2024: $409 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $619.96 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $325.08 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $244.51 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $239.86 | 2023-2025 | Jynarque |
| Amgen INC. | $142.32 | 2019-2025 | Tavneos, Krystexxa |
| Vantive US Healthcare LLC | $117.17 | 2025 | Renal - Pd |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.34 | 2024 | |
| Calliditas Therapeutics US INC. | $44.24 | 2024 | |
| Fresenius USA Marketing, INC. | $42.12 | 2019-2023 | Korsuva, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.64 | 2025 | Jardiance |
| Cycle Pharmaceuticals INC | $19.88 | 2024 | Tiopronin |
| Akebia Therapeutics INC | $19.52 | 2025 | Vafseo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.71 | 2024 | |
| Baxter Healthcare | $16.29 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biobeat USA INC. | $15.58 | 2024 | Bb-613 Bpm Kit |
| Ardelyx, INC. | $15.21 | 2024 | Ibsrela |
| Aurinia Pharma U.S., INC. | $14.48 | 2025 | Lupkynis |
| Allergan, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graeme Mindel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.